HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘FASTER’ Path For US FDA To Identify Allergens, Impose Related Rules Passes House Committee

Executive Summary

“Food Allergy Safety, Treatment, Education, and Research Act of 2019” would amend FDA regulations to include sesame as major allergen and allow agency to add other ingredients as major allergens based on prevalence and severity of allergic reactions. Separately, FDA FY2021 budget part of minibus set for House vote week of 20 July.

You may also be interested in...



US FDA Guidance Scratches Sesame Labeling Itch; House Passes ‘FASTER’ Allergen Identity Process

Food Allergy Safety, Treatment, Education, and Research Act would amend FDA regulations to include sesame as major allergen and allow agency to add other food ingredients as major allergens based on prevalence and severity of allergic reactions. FDA, meanwhile, published guidance for voluntarily labeling sesame as an allergen while it develop its factors for evaluating which food allergens in addition to the eight already specified in its regulations should be designated as requiring additional controls, including allergen labeling.

Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work

Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.

Expanding US FDA Mandatory Recall Authority To All Drugs Gets House Appropriators’ Approval

Appropriators’ FDA FY 2021 budget includes amendment to expand its mandatory recall authority introduced by chairman of subcommittee with oversight of agency’s budget, Rep. Sanford Bishop. He said the agency should be able to force drug product recalls as it already can for vaccines, medical devices and products containing ingredients also scheduled as controlled substances.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel